Literature DB >> 22110004

Minimally invasive insertion of an equine stented pulmonary valve with a built-in sinus portion in a sheep model.

Ali Dodge-Khatami1, Stefan Hallhagen, Kuno Limacher, Björn Söderberg, Rolf Jenni.   

Abstract

OBJECTIVES: This study evaluated the feasibility of inserting a new equine stented-valve with a sinus portion in a lamb survival model, through a minimally invasive thoracotomy with right ventricular access without cardiopulmonary bypass.
BACKGROUND: Extant surgical or percutaneous methods for inserting biological valves in the right outflow tract have drawbacks and limitations.
METHODS: A decellularized equine valved jugular vein, sutured to a self-expanding stent with a sinus portion, was placed through a minimal right thoracotomy using a newly developed flexible hydraulic release device in seven lambs. The approach through the right ventricle into the pulmonary valve position is achieved on a beating heart.
RESULTS: The stented valves were correctly positioned in the right outflow tract, were competent up to 6 months as confirmed by angiography and echocardiography, and were well-tolerated by the animals, with endothelialization of the valve demonstrated at 6 months.
CONCLUSIONS: The newly developed hydraulic release system allowed for safe and reliable insertion of an equine stented-valve with a sinus portion, through a right transventricular approach on a beating heart, in a sheep survival model.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 22110004     DOI: 10.1002/ccd.23354

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  1 in total

1.  Development of an Off-the-Shelf Tissue-Engineered Sinus Valve for Transcatheter Pulmonary Valve Replacement: a Proof-of-Concept Study.

Authors:  Sarah E Motta; Emanuela S Fioretta; Petra E Dijkman; Valentina Lintas; Luc Behr; Simon P Hoerstrup; Maximilian Y Emmert
Journal:  J Cardiovasc Transl Res       Date:  2018-03-20       Impact factor: 4.132

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.